{"protocolSection": {"identificationModule": {"nctId": "NCT00890591", "orgStudyIdInfo": {"id": "SPB-OM-0106"}, "organization": {"fullName": "Daiichi Sankyo", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension", "officialTitle": "National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine Besylate", "acronym": "Benibest"}, "statusModule": {"statusVerifiedDate": "2009-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-08"}, "primaryCompletionDateStruct": {"date": "2007-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-02-11", "studyFirstSubmitQcDate": "2009-03-20", "studyFirstPostDateStruct": {"date": "2009-04-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-02-11", "resultsFirstSubmitQcDate": "2009-03-20", "resultsFirstPostDateStruct": {"date": "2009-04-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2009-05-27", "lastUpdatePostDateStruct": {"date": "2009-06-03", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Medical Affairs Manager", "oldOrganization": "Daiichi Sankyo Brazil"}, "leadSponsor": {"name": "Daiichi Sankyo", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2 phases), addition of amlodipine."}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["hypertension", "angiotensin II type 1 receptor blocker", "olmesartan"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 144, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment", "type": "EXPERIMENTAL", "interventionNames": ["Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary"]}], "interventions": [{"type": "DRUG", "name": "olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary", "description": "olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks", "armGroupLabels": ["Treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy)", "description": "Number of patients that achieved a blood pressure (BP) goal of less than 130/85 in the first group (olmesartan monotherapy 20 mg). If BP was \\> or = to 140/90 at 4,8, or 9 wks the participant went to next level for an additional 4-9 weeks at the next medication level", "timeFrame": "4 - 9 wks of olmesartan monotherapy"}, {"measure": "Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in First Titrated Group (Olmesartan 20 mg + 12.5 mg Hydrochlorothiazide)", "description": "Number of patients that achieved a blood pressure goal of less than 130/85 in first titrated group (olmesartan 20 mg + 12.5 mg hydrochlorothiazide)If BP was \\> or = to 140/90 at 4,8, or 9 wks the participant went to next level of medication for an additional 4-9 weeks", "timeFrame": "4 to 9 weeks on combination therapy"}, {"measure": "Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Second Titrated Group (Olmesartan 40 mg + 25 mg Hydrochlorothiazide)", "description": "Number of patients that achieved a blood pressure goal of less than 130/85 in second titrated group (olmesartan 40 mg + 25 mg hydrochlorothiazide). If BP was \\> or = to 140/90 at 4,8, or 9 wks the participant went to next level of medication for an additional 4-9 weeks.", "timeFrame": "4 to 9 weeks"}, {"measure": "Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Third Titrated Group (Olmesartan + Hydrochorothiazide + Amlodipine)", "description": "Number of patients that achieved a blood pressure goal of less than 130/85 in third titrated group (olmesartan 40 mg + 25 mg hydrochlorothiazide + amlodipine 5 mg). This combination was maintained as long as the participant's blood pressure remained within predefined parameters. If not, participant discontinued for lack of efficacy.", "timeFrame": "4 - 9 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Stage 1 and 2 hypertension without treatment for at least 2 weeks\n* Women with no risk of becoming pregnant\n\nExclusion Criteria:\n\n* Study participation could result in risk to health of subject\n* Cardiovascular disease\n* Secondary hypertension or stage 3 hypertension\n* Myocardial infarction within the last 6 months\n* Congestive heart failure\n* Pulmonary edema\n* Valvular alterations or rheumatic cardiopathy\n* Clinically relevant conduction disorders significant arrhythmias\n* Alcohol or illicit drug use\n* Medication abuse\n* Pregnant or nursing women", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "30 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A wash out period was needed in case of a previous inefficient antihypertensive medication, so it was interrupted from 2 to 3 wks before the enrollment. The patient could be excluded considering the exclusion criteria.", "recruitmentDetails": "The study pop. was defined by the inclusion criteria. This study was carried out in 14 centers in Brazil with inclusion 2 months after the first study subject, started in Aug 06. After the screening visit, the patients that met inclusion and exclusion criteria were selected to participate in the study. The last patient out was in Jul 07.", "groups": [{"id": "FG000", "title": "Olmesartan + Hydrochlorothiazide + Amlodipine", "description": "1. olmesartan monotherapy was the starting dosage regimen. Blood pressure (BP) measurments were obtained at 4, 8 and 9 weeks. If BP goals were not met at a measurment point the participant's medication was elevated to the next step and BP measurments taken at the next 4, 8, and 9 weeks.\n2. olmesartan 20 mg/ hydrochlorothiazide 12.5 mg tablets was the first titration regimen if blood pressure goals were not achieved\n3. olmesartan 40 mg + hydrochlorothiazide 25 mg tablets was the second titration regimen if blood pressure goals were not achieved\n4. olmesartan 40 mg + hydrochlorothiazide 25 mg tablets + amlodipine 5 mg tablets was the third titration regimen if blood pressure goals were not achieved"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "144"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "124"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "20"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Olmesartan + Hydrochlorothiazide + Amlodipine", "description": "1. olmesartan monotherapy was the starting dosage regimen. Blood pressure (BP) measurments were obtained at 4, 8 and 9 weeks. If BP goals were not met at a measurment point the participant's medication was elevated to the next step and BP measurments taken at the next 4, 8, and 9 weeks.\n2. olmesartan 20 mg/ hydrochlorothiazide 12.5 mg tablets was the first titration regimen if blood pressure goals were not achieved\n3. olmesartan 40 mg + hydrochlorothiazide 25 mg tablets was the second titration regimen if blood pressure goals were not achieved\n4. olmesartan 40 mg + hydrochlorothiazide 25 mg tablets + amlodipine 5 mg tablets was the third titration regimen if blood pressure goals were not achieved"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "144"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "132"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "12"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "74"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "70"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "83"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Brazil", "categories": [{"measurements": [{"groupId": "BG000", "value": "144"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy)", "description": "Number of patients that achieved a blood pressure (BP) goal of less than 130/85 in the first group (olmesartan monotherapy 20 mg). If BP was \\> or = to 140/90 at 4,8, or 9 wks the participant went to next level for an additional 4-9 weeks at the next medication level", "populationDescription": "In this first dosage group 144 started and 38 patients met their blood pressure goal; therefore, 106 started the first titration regimen. There were no dropouts.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4 - 9 wks of olmesartan monotherapy", "groups": [{"id": "OG000", "title": "Olmesartan Monotherapy", "description": "olmesartan monotherapy 20 mg for 4-9 weeks based on blood pressure (BP) measurements at 4, 8 or 9 weeks. Participant went to next treatment if BP \\> or = to 140/90 mm Hg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "38"}]}]}]}, {"type": "PRIMARY", "title": "Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in First Titrated Group (Olmesartan 20 mg + 12.5 mg Hydrochlorothiazide)", "description": "Number of patients that achieved a blood pressure goal of less than 130/85 in first titrated group (olmesartan 20 mg + 12.5 mg hydrochlorothiazide)If BP was \\> or = to 140/90 at 4,8, or 9 wks the participant went to next level of medication for an additional 4-9 weeks", "populationDescription": "In this first titration group 106 patients started and 33 achieved their blood pressure goal. There were no dropouts and 73 subject started the second titration regimen.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4 to 9 weeks on combination therapy", "groups": [{"id": "OG000", "title": "Olmesartan + Hydrochlorothiazide", "description": "olmesartan 20 mg/hydrochlorothiazide 12.5 mg tablets for 4-9 weeks based on blood pressure (BP) measurements at 4, 8 or 9 weeks. Participant went to next treatment if BP \\> or = to 140/90 mm Hg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33"}]}]}]}, {"type": "PRIMARY", "title": "Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Second Titrated Group (Olmesartan 40 mg + 25 mg Hydrochlorothiazide)", "description": "Number of patients that achieved a blood pressure goal of less than 130/85 in second titrated group (olmesartan 40 mg + 25 mg hydrochlorothiazide). If BP was \\> or = to 140/90 at 4,8, or 9 wks the participant went to next level of medication for an additional 4-9 weeks.", "populationDescription": "73 patients started the second titration regimen and 41 met their blood pressure goal. There were no dropouts. 32 started the final titration regimen.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4 to 9 weeks", "groups": [{"id": "OG000", "title": "Olmesartan + Hydrochlorothiazide", "description": "olmesartan 40 mg/+ hydrochlorothiazide 25 mg tablets for 4-9 weeks based on blood pressure (BP) measurements at 4, 8 or 9 weeks. Participant went to next treatment if BP \\> or = to 140/90 mm Hg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41"}]}]}]}, {"type": "PRIMARY", "title": "Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Third Titrated Group (Olmesartan + Hydrochorothiazide + Amlodipine)", "description": "Number of patients that achieved a blood pressure goal of less than 130/85 in third titrated group (olmesartan 40 mg + 25 mg hydrochlorothiazide + amlodipine 5 mg). This combination was maintained as long as the participant's blood pressure remained within predefined parameters. If not, participant discontinued for lack of efficacy.", "populationDescription": "32 subjects started the third and final titration regimen and 12 met their blood pressure goals. 20 dropped out for lack of efficacy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "4 - 9 weeks", "groups": [{"id": "OG000", "title": "Olmesartan + Hydrochlorothiazide + Amlodipine", "description": "olmesartan 40 mg/+ hydrochlorothiazide 25 mg tablets + amlodipine tablets 5 mg for 4-9 weeks based on blood pressure (BP) measurements at 4, 8 or 9 weeks. Participant went to next treatment if BP \\> or = to 140/90 mm Hg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12"}]}]}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Howard Kessler", "organization": "Daiichi Sankyo Pharma Development", "email": "hmkessler@dsus.com", "phone": "732-590-5032"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000437965", "term": "Olmesartan"}, {"id": "D000068557", "term": "Olmesartan Medoxomil"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M91890", "name": "Olmesartan", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M273", "name": "Olmesartan Medoxomil", "asFound": "Sleep hygiene", "relevance": "HIGH"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}